| Home | E-Submission | Sitemap | Contact Us
top_img
Cancer Research and Treatment > Volume 43(4); 2011 > Article
Jang, Jung, and Kim: Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers

Abstract

Purpose

About 10% of all gastric cancers (GCs) are Epstein-Barr virus (EBV)-associated. However, the oncogene of EBV in gastric carcinogenesis has not yet been established. In the present study, we investigated the virus-derived transcripts in the EBV-infected GC cell line to explore the viral oncogene of EBV-positive GCs.

Materials and Methods

We used the SNU719 cell line, a naturally derived EBV-infected GC cell line. The individual expressed sequence tags from the cDNA libraries of SNU719 were searched against the mRNA subset extracted from the GenBank data base. Sequence reaction was carried out for the EBV-associated clones. Reverse transcription-polymerase chain reaction was performed after cells were partitioned into nuclear and cytoplasmic fractions.

Results

Using bioinformatic tools, we selected 13 EBV-associated clones from cDNA libraries of SNU719. By sequencing analysis, we revealed that they were all associated with RPMS1, one of the BamHI-A rightward transcripts (BART) of EBV. Some BART cDNAs such as RPMS1 and A73 are known to be translated into protein in vitro, and have been shown to have some biochemical functions relevant to tumorigenesis. But, presently, the BART transcripts were expressed only in the nucleus and not in the cytoplasm, arguing against their role as messenger RNAs. Some other BART transcripts expressed in GCs (BARF0, CST, vIL, BARF1, BLLF1, and BcLF1) were also extensively detected in the nucleus.

Conclusion

BART transcripts are the predominant viral transcripts expressed in EBV-associated GCs, and they are located only in the nucleus. Therefore, it seems less likely that BART transcripts produce functional proteins to play a role in carcinogenesis of EBV-associated GCs.

Introduction

Epstein-Barr virus (EBV) has been implicated in the development of a wide range of cancers such as nasopharyngeal carcinoma (NPC), Hodgkin's disease, and Burkitt's lymphoma since its discovery as the first human tumor virus [1]. EBV encodes multiple viral proteins, and the expression patterns of those proteins in human malignancies are variable. Some of viral products such as latent membrane protein (LMP)-1 and EBV nuclear antigen 2 have been suggested to be important in the oncogenic process of many EBV-associated cancers.
EBV is found in approximately 10% of gastric cancers (GCs) [2], and is proposed to have a critical role in EBV-associated GCs since the virus is present all cancer cells and carcinoma is formed by the proliferation of a single EBV infected cell [3]. However, the specific genes from EBV genome contributing to the carcinogenesis of GCs still remain unknown. The latency pattern in EBV-carrying GCs is distinct from the other EBV-associated malignancies by the absence of LMP 1, LMP2B [4] and the expression of the BARF1 [5]. Some EBV genes are suggested to have an oncogenic role in EBV-carrying GCs. For example, BARF1, which is exclusively expressed in EBV-associated GCs, has oncogenic properties in many cell types such as monkey kidney epithelial cell line [6] and human B lymphocytes [7], and human epithelial cell line HBE [8]. In addition, cyclin D1 induced in BARF1-transfected epithelial cells was overexpressed in EBV-associated GCs, indicating an interaction of viral BARF1 and cyclin D1 [9]. However, BARF1 transcripts have never been shown to produce protein in EBV-positive GCs. Thus, it requires further study to confirm the oncogenic role of BARF1 in EBV-associated GCs.
As EBV-infected GC cells show the specific latency pattern of viral gene expression and usually do not express the major oncogenic LMP1, we tried to identify the specific transcripts implicated in the carcinogenesis of EBV-positive GCs from EBV-infected gastric cancer cell lines. In this study, we searched for EBV-associated clones in cDNA libraries established from the EBV-infected GC cell line, SNU719, to find novel viral oncogenes in GCs, and investigated their expression in SNU719 cells.

Materials and Methods

1. Cell line

The SNU719 cell line was used. It is a naturally derived EBV-infected cell line, which was established from a 53-year-old male patient with primary stomach cancer tissue in July 1991 [10]. It was obtained from the Korean Cell Line Bank (Seoul, Korea) and was cultured in RPMI-1640 supplemented with 10% heat-inactivated FBS (Hyclone, Logan, UT) at 37℃ in a humidified CO2 incubator.

2. Bioinformatic analysis of EBV-associated expressed sequence tags (ESTs)

Two cDNA libraries derived from SNU719 are available in the National Center for Biotechnology Information (NCBI) UniGene database (http://www.ncbi.nlm.nih.gov/unigene). The individual ESTs were searched against the mRNA subset extracted from the GenBank data base. The selected clones were obtained from 21C frontier Gene Bank (Daejeon, Korea). Plasmid DNAs were extracted and sequencing reactions were performed using a BigDye Terminator Sequencing kit (Applied Biosystems, Foster City, CA). After the unincorporated dye terminator was removed from the sequencing reaction, the reaction products were applied to genetic analyzers (Applied Biosystems).

3. Reverse transcriptase polymerase chain reaction (RT-PCR)

After cells were partitioned into nuclear and cytoplasmic fraction, RNA was extracted by PARIS (Ambion, Austin, TX). Five hundred nanograms of RNA were used to synthesize cDNA using a random hexamers. Reverse transcription was carried out with Superscript Reverse Transcriptase (Invitrogen, Carlsbad, CA). PCR was performed with primers which were used in the previous studies [11,12]. The PCR reaction mixture consisted of 1× PCR premix (Takara, Shiga, Japan), 5 pmol of each primer, and 1 µL of cDNA. PCR involved 25 cycles of 95℃, 30 seconds; 50-60℃, 30 seconds; 72℃, 1 minute followed by 10 minutes at 72℃ to complete reaction. This experiment was repeated three times.

Results

1. Analysis of EBV-associated ESTs from the SNU719 cDNA library

ESTs are useful for the differential and quantitative analysis for the evaluation of gene expression profiles in a given tissue. We found two SNU719 cDNA libraries (S7SNU719 and S7SNU719S1) established from SNU719, EBV-infected gastric cancer cell line in NCBI's UniGene database. The total number of ESTs from the two libraries was 4,701. The individual EST was searched against the mRNA subset extracted from the GenBank data base. We selected 13 clones that had a possibility of being transcribed from the EBV genome by Blast analysis. After each clone was linearized with EcoR I and Not I, it was electrophoresed in 1% agarose gel (Fig. 1). We classified them into five groups based on size. Sequencing the clone from each five groups revealed that three groups of clones-1.2 kb, 1.6 kb, and 2.5 kb-were derived from EBV genome and were related with the RPMS1 transcript that spans the whole BamHI-A rightward transcript (BART) region of EBV (Table 1). BART transcripts are a group of various splicing variants transcribed from 138352 to 160531 on the wild-type EBV genome, and some open reading frames (ORFs) in those BART cDNAs have been actively investigated such as RPMS1 and A73. Through BLAST sequence alignment, three groups of clones were included in RPMS1 cDNA. Group 3 clone covered most of the ORF of RPMS1, whereas Group 1 and 2 clones showed no overlap with any ORFs of RPMS1 and A73 (Fig. 2).

2. Analysis of cytoplasmic and nuclear EBV transcripts from EBV-infected gastric cancer cell lines

Some BARTs such as RPMS1 and A73 have ORFs, and they have been shown to produce proteins in vitro with significant biologic functions relevant to carcinogenesis. However, it has never been demonstrated in naturally EBV infected cells. Since we identified the various BARTs in EBV-associated GC, we decided to investigate whether or not they might be acting as mRNAs. If gene transcripts act as mRNAs, they will be detected in the cytoplasm. Therefore, we probed for BART RNAs of SNU719 in the cytoplasm. After cells were partitioned into nuclear and cytoplasmic fractions, RNA was extracted and RT-PCR was performed with primers specific for the spliced exons 3B-5 and 5-7 of BART. BART RNA was almost completely in the nucleus (Fig. 3A). Some latent and lytic transcripts that are expressed in EBV-associated GCs were also detected in the nucleus only (Fig. 3B). However, we were not able to confirm the expression of BART transcripts by Northern blot analysis. Although we did not detect any BART transcripts in the cytoplasm of SNU719 cells, it is still possible that BART transcripts might have been translated into protein that functioned in the development of GCs. This role would likely have been in the early stage of tumorigenesis, but not in fully developed cancer cells. We are planning to try RNA in situ hybridization for paraffin embedded tissues to further explore the cytosolic BART transcripts in dysplastic cells triggered by EBV infection, which is expected to clarify the existence of BARTs in many different stages of gastric epithelial cells undergoing transformation.

Discussion

BART RNAs were originally identified by analysis of the cDNA libraries established from the NPC cell line [13]. Since then, they have been demonstrated to be expressed in many EBV-associated malignancies including EBV-positive GCs. In this study, we identified some BART RNAs in the EBV-positive GC cell line. It is notable that all EBV-related clones that we found from the cDNA library of EBV-positive GC cell line turned out to be related with BART, which suggests that BART RNAs are quite possibly the predominant transcripts from EBV genome in EBV-infected GCs.
Among these clones, the largest one (2.5 kb) contained the ORF of RPMS1 indicating that RPMS1 protein might be translated if that cDNA acts as mRNA. In fact, RPMS1 already has been shown to produce a nuclear protein in vitro, which could be detected using specific antibodies that recognize artificially expressed RPMS1 protein. These findings strongly support the possibility that RPMS1 could act as mRNA in vivo. However, we observed RPMS1 transcripts exclusively expressed in the nucleus of EBV-positive GC cells by performing RT-PCR after nuclear/cytoplasmic fractionation, which argues against them acting as mRNAs. Furthermore, previous studies also failed to detect the endogenous RPMS1 protein in NPC or Burkitt lymphoma cases with the specific monoclonal antibodies that were verified to be able to detect the recombinant RPMS1 protein [11,14,15]. Thus, it still remains uncertain that RPMS1 transcripts produce a detectable protein in natural EBV infections.
Despite the lack of evidence of its acting as mRNA, RPMS1 clearly has some biologic functions that are quite relevant to tumorigenesis. Artificially expressed RPMS1 protein antagonizes the transcription activation by Notch 1 or EBVA2 through its interaction with the CBF1-associated corepressor complex [15], and enhances anchorage-independent growth of 293 cells and produce tumors in nude mice [16]. A73, another BARTs-derived potential protein, has been translated in vitro and was shown to bind to the cellular RACK1 and regulate calcium influx, even though the existence of endogenous A73 protein has never been demonstrated [11]. These biologic functions could fit well with a pathologic role of EBV in EBV-related cancers. Therefore, the possibility still remains, and we can speculate that RPMS1 might be transiently expressed in specific circumstances only and contribute to the development of cancer. For example, RPMS1 might be translated into the protein under a certain precancerous stage, but not fully-developed cancer cells. Thus, it could be meaningful to try to investigate the presence of RPMS1 protein in non-cancer cells that are only infected by EBV or cells that are show dysplastic changes after EBV infection.
The abundant BART RNA transcripts have been implicated in carcinogenesis by contributing to the production of miRNAs. Since the first discovery of EBV miRNAs from the Burkitt's lymphoma cells, over 20 miRNAs have been identified [17,18]. These miRNAs were shown to be present in EBV-infected GC cell lines and the tumor tissues from patients [19]. Some targets for miRNAs have been unraveled such as EBV DNA polymerase [20], EBV LMP1 [21], and p53 up-regulated modulator of apoptosis [22]. Interestingly, these miRNAs are derived mainly from the introns prior to splicing of the BART primary transcripts, and their expression is largely predicted by the level of expression of the BART RNAs [18]. Based on the close correlation of expression of BART transcripts and BART miRNAs, it can be suggested that the primary goal of the transcription of BART might be to promote the production of miRNAs, not to produce the viral proteins. Alternatively, BART transcripts might have dual functions, serving as oncogenic proteins in precancerous stage and then supplying miRNAs to support cell survival or immune evasion in established cancer cells.

Conclusion

In this study, we showed that BART transcripts are the predominant viral transcripts expressed in EBV-associated GCs. We also observed they are located in the nucleus only, indicating that BART transcripts are less likely to produce functional proteins than they are to play a role in carcinogenesis of EBV-associated GCs.

Acknowledgments

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (101146).

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

References

1. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803–821. PMID: 14871955.
crossref
2. Takano Y, Kato Y, Saegusa M, Mori S, Shiota M, Masuda M, et al. The role of the Epstein-Barr virus in the oncogenesis of EBV(+) gastric carcinomas. Virchows Arch. 1999;434:17–22. PMID: 10071230.
crossref
3. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol. 2000;53:255–261. PMID: 11091849.
crossref
4. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, et al. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer. 1996;74:625–631. PMID: 8761381.
crossref
5. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res. 2000;60:2745–2748. PMID: 10825150.
pmid
6. Kim do N, Song YJ, Lee SK. The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines. Exp Mol Med. 2011;43:401–410. PMID: 21628990.
crossref
7. Lee JE, Hong EJ, Nam HY, Kim JW, Han BG, Jeon JP. MicroRNA signatures associated with immortalization of EBV-transformed lymphoblastoid cell lines and their clinical traits. Cell Prolif. 2011;44:59–66. PMID: 21199010.
crossref
8. Song LB, Zen MS, Zhang L, Li MZ, Liao WT, Zheng ML, et al. Effect of EBV encoded BARF1 gene on malignant transformation of human epithelial cell line HBE. Ai Zheng. 2004;23(11 Suppl):1361–1364. PMID: 15566637.
pmid
9. Wiech T, Nikolopoulos E, Lassman S, Heidt T, Schöpflin A, Sarbia M, et al. Cyclin D1 expression is induced by viral BARF1 and is overexpressed in EBV-associated gastric cancer. Virchows Arch. 2008;452:621–627. PMID: 18437417.
crossref
10. Oh ST, Seo JS, Moon UY, Kang KH, Shin DJ, Yoon SK, et al. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology. 2004;320:330–336. PMID: 15016554.
crossref
11. Al-Mozaini M, Bodelon G, Karstegl CE, Jin B, Al-Ahdal M, Farrell PJ. Epstein-Barr virus BART gene expression. J Gen Virol. 2009;90(Pt 2):307–316. PMID: 19141439.
crossref
12. Jung EJ, Lee YM, Lee BL, Chang MS, Kim WH. Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line. Anticancer Drugs. 2007;18:79–85. PMID: 17159505.
crossref pmid
13. Hitt MM, Allday MJ, Hara T, Karran L, Jones MD, Busson P, et al. EBV gene expression in an NPC-related tumour. EMBO J. 1989;8:2639–2651. PMID: 2479554.
pmid pmc
14. Smith PR, de Jesus O, Turner D, Hollyoake M, Karstegl CE, Griffin BE, et al. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol. 2000;74:3082–3092. PMID: 10708423.
crossref
15. Zhang J, Chen H, Weinmaster G, Hayward SD. Epstein-Barr virus BamHi-a rightward transcript-encoded RPMS protein interacts with the CBF1-associated corepressor CIR to negatively regulate the activity of EBNA2 and NotchIC. J Virol. 2001;75:2946–2956. PMID: 11222720.
crossref
16. Li A, Zhang XS, Jiang JH, Wang HH, Liu XQ, Pan ZG, et al. Transcriptional expression of RPMS1 in nasopharyngeal carcinoma and its oncogenic potential. Cell Cycle. 2005;4:304–309. PMID: 15725729.
crossref
17. Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. Science. 2004;304:734–736. PMID: 15118162.
crossref
18. Edwards RH, Marquitz AR, Raab-Traub N. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol. 2008;82:9094–9106. PMID: 18614630.
crossref
19. Kim do N, Chae HS, Oh ST, Kang JH, Park CH, Park WS, et al. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol. 2007;81:1033–1036. PMID: 17079300.
crossref
20. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res. 2008;36:666–675. PMID: 18073197.
crossref
21. Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A. 2007;104:16164–16169. PMID: 17911266.
crossref
22. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med. 2008;205:2551–2560. PMID: 18838543.
crossref
Fig. 1
Electrophoresis of 13 clones after digestion with EcoR I and Not I. Clones 1, 2, 4, 6, 10, 11 and 13 showed two fragments of 1.2 kb and 0.4 kb because of their EcoR I recognition sites.
crt-43-250-g001
Fig. 2
Sequence alignment of three groups of clones to the RPMS1 cDNA. The BLAST sequence alignment program was used to compare the sequence of the clones to RPMS1. The open reading frames (ORFs) of RPMS1 and A73 are shown by boxed segments.
crt-43-250-g002
Fig. 3
Analysis of Epstein-Barr virus (EBV) transcripts comparing cytoplasmic and nuclear RNA from SNU719. (A) Reverse transcriptase polymerase chain reaction (RT-PCR) for BamHI-A rightward transcripts (BART) RNAs using primers spanning BART exons 3B-5 or 5-7. (B) RT-PCR for the some latent and lytic EBV transcripts. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as an internal control.
crt-43-250-g003
Table 1
Summary of clones according to size
Clone number Size of clone (kb) Associated gene of
Epstein-Barr virus
Group 1a) 1, 2, 4, 6, 10, 11, 13 1.6 RPMS1
Group 2 7, 8, 9 1.2 RPMS1
Group 3 12 12 RPMS1
Group 4 3 0.3 None
Group 5 5 1 None

a)The clones of Group 1 have an EcoR I recognition site that generated two segments of 1.2 kb and 0.4 kb after digestion with EcoR I and Not I.

Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 110-999, Korea
TEL: +82-2-792-1486   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community